CA266-0008: ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)

Sponsor:

Bristol Myers Squibb

Sponsor Study ID:

CA266-0008

CTO #:

104292

NCT Number:

NCT07293351

Phase:

I/II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Kidney

Study Objectives:

To evaluate the safety and tolerability, and to determine the RP2D, of pumitamig administered in combination with ipilimumab or cabozantinib regiment in participants with renal cell carcinoma. To evaluate the ORR of pumitamig administered in combination with ipilimumab or cabozantinib in participants with first-line renal cell carcinoma.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)